Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05182073 · ClinicalTrials.gov registry record · Phase 1
FT576 in Subjects With Multiple Myeloma
A Phase 1 study, sponsored by Fate Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT05182073 is a Phase 1 study that has completed, run by Fate Therapeutics. The registered enrollment target is 31 participants.
The verdict
NCT05182073, a Phase 1 study, has completed, sponsored by Fate Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Daratumumab
- DRUG Bendamustine
- DRUG FT576 (Allogenic CAR NK cells with BCMA expression)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2021-11-10 |
| Est. Completion | 2024-10-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05182073
The ClinicalTrials.gov registry entry for NCT05182073 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Fate Therapeutics, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT05182073 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05182073 about?
NCT05182073 is a clinical study titled "FT576 in Subjects With Multiple Myeloma". This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.
What is the current status of trial NCT05182073?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2021-11-10. Estimated completion is 2024-10-18.
What interventions are being tested in trial NCT05182073?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Daratumumab (DRUG), Bendamustine (DRUG), FT576 (Allogenic CAR NK cells with BCMA expression) (DRUG).
Who is sponsoring clinical trial NCT05182073?
This trial is sponsored by Fate Therapeutics, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.